A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2+ breast cancer: The TRAIN-2 study (BOOG 2012-03)
Mette S. Van Ramshorst, Erik van Werkhoven, Ingrid A. Mandjes, Inge Kemper, Vincent O. Dezentjé, Irma M. Oving, Aafke H. Honkoop, Lidwine W Tick, Agnes W Van de Wouw, Caroline M Mandigers, Jelle Wesseling, Marie-Jeanne Vrancken Peeters, Sabine C. Linn, Gabe S. Sonke
Dutch Breast Cancer Research Group (BOOG)
Netherlands Cancer Institute, Amsterdam, Netherlands
Reinier de Graaf Groep, Delft, Netherlands
Ziekenhuisgroep Twente (ZGT), Almelo, Netherlands
Isala Clinics, Zwolle, NetherlandsMáxima Medical Center, Eindhoven, Netherlands
Viecuri Medical Centre, Venlo, Netherlands
Canisius Wilhelmina Hospital, Nijmegen, Netherlands
Department of Medical Oncology- Antoni van Leeuwenhoek Hospital, Netherlands Cancer Institute, Amsterdam, NetherlandsView Less
Meeting: 2017 ASCO Annual Meeting Track: Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy Abstract number: 507 Citation: J Clin Oncol 35, 2017 (suppl; abstr 507) Author(s): Mette S. Van Ramshorst, Erik van Werkhoven, Ingrid A. Mandjes, Inge Kemper, Vincent O. Dezentjé, Irma M. Oving, Aafke H. Honkoop, Lidwine W Tick, Agnes W Van de Wouw,...